Nivolumab and Ipilimumab in Metastatic Melanoma Are Associated with Distinct Immune Landscape Changes and Response-Associated Immunophenotypes
D. M. Woods, A. S. Laino, A. F. Winters, J. M. Alexandre, V. Rao, S. S. Adavani, J. S. Weber, P. K. Chattopadhyay
This study compares immune landscape changes and immunophenotypes in metastatic melanoma patients treated with nivolumab and ipilimumab, finding distinct associations with treatment response and survival.
bioRxiv · Jan 13, 2020Immunology